Published in Research

Iridex releases part 2 of MicroPulse evidence-based guideline series

This is editorially independent content
3 min read

Iridex Corporation announced that the second part of the evidence-based guidelines series on MicroPulse transscleral laser therapy (MP-TLT) has been published in Clinical Ophthalmology.

What is MP-TLT?

Micropulse trans-scleral laser therapy (MP-TLT) is a non-incisional laser procedure performed using the Iridex Cyclo G6 laser (in the micropulse treatment mode) with the MicroPulse P3 probe to treat primary and secondary forms of glaucoma.

The technology delivers repetitive and short “on” pulses that are followed by longer “off” periods in order to control increasing temperatures and prevent thermal buildup in the tissue—delivering an intended effect to targeted tissue.

What’s the intent?

MP-TLT is intended to provide a significant lowering of intraocular pressure (IOP), leading to it being usable for a wider range of glaucoma patients.

What did the first part of the guidelines cover?

Published in 2022, part 1 included 100% consensus-based guidelines—established by 10 glaucoma experts from across the globe—on patient dosimetry and patient selection based on a complete analysis of MP-TLT from a clinical, technical, and practice experience (to date) standpoint.

They concluded MP-TLT to be a useful addition to the glaucoma armamentarium.

See the full findings here.

How about part 2?

The second set of guidelines for the use of a revised version of the MicroPulse P3 and Iridex Cyclo G6 laser that cover anesthesia, surgical technique, postoperative care, expected outcomes, setting adjustment as well as enhancements, and retreatments.

How was the data gathered?

Glaucoma experts conducted a comprehensive search that led to an analysis of 61 studies on MP-TLT  and the use of a three-round Delphi method involving MP-TLT experts for guidance in areas where literature was lacking detail and specificity.


The experts concluded that, when used with proper technique and patient selection—as well as within appropriate treatment parameters—MP-TLT is an effective and well-tolerated treatment for glaucoma of varying severities and types.

These findings mirror that of the first part of the guidelines.

Anything else?

The guidelines offer eyecare professionals insight on maximizing the tolerability and effectiveness of MP-TLT for glaucoma for patients.

See here to watch the expert panel discuss the findings of both part 1 and part 2 of the consensus.